Annexin Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 229.3%.

Top 20 shareholders own 53.62% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
16.9%	Mikael Lonn	90,276,060	SEK 67.3m	0.62%	no data
12%	Arne Andersson	64,041,911	SEK 47.8m	143%	no data
5.51%	Sebastian Jahreskog	29,348,380	SEK 21.9m	148%	no data
4.92%	Magnus Claesson	26,245,066	SEK 19.6m	144%	no data
4.12%	Lars Hallén	21,983,544	SEK 16.4m	0%	no data
1.8%	Nordnet AB (publ), Asset Management Arm	9,613,523	SEK 7.2m	123%	0.08%
1.66%	Thorbjörn Fridh	8,825,000	SEK 6.6m	0%	no data
1.41%	Mattias Willman	7,507,061	SEK 5.6m	156%	no data
1.26%	Avanza Fonder AB	6,740,524	SEK 5.0m	125%	0.01%
1.17%	Lars Hallen	6,240,000	SEK 4.7m	0%	no data
1.09%	Medirista Ab	5,783,918	SEK 4.3m	1,050%	no data
0.82%	Torbjörn Fridh	4,355,000	SEK 3.2m	0%	no data
0.44%	Frostskog Ab	2,369,296	SEK 1.8m	0%	no data
0.21%	Anders Haegerstrand	1,130,608	SEK 843.4k	14.8%	no data
0.12%	Carl-Fredrik Lindner	640,005	SEK 477.4k	357%	no data
0.039%	Uli Hacksell	210,000	SEK 156.7k	110%	no data
0.036%	Susan Suchdev	189,560	SEK 141.4k	175%	no data
0.033%	Henrik Palm	175,000	SEK 130.5k	0%	no data
0.0089%	Anthon Jahreskog	47,649	SEK 35.5k	110%	no data
0.0083%	Gisela Sitbon	44,100	SEK 32.9k	110%	no data